Asia Biotech Profile
Key Indicators
- Authorised Capital ₹ 8.00 M
as on 16-07-2024
- Paid Up Capital ₹ 7.00 M
as on 16-07-2024
- Company Age 12 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.18 Cr
as on 16-07-2024
- Satisfied Charges ₹ 1.97 Cr
as on 16-07-2024
- Revenue -9.53%
(FY 2023)
- Profit -20.81%
(FY 2023)
- Ebitda -20.20%
(FY 2023)
- Net Worth 7.05%
(FY 2023)
- Total Assets -8.67%
(FY 2023)
About Asia Biotech
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 8.00 M and a paid-up capital of Rs 7.00 M.
The company currently has active open charges totaling ₹1.18 Cr. The company has closed loans amounting to ₹1.97 Cr, as per Ministry of Corporate Affairs (MCA) records.
Ashish Khandelwal and Nirmla Khandelwal serve as directors at the Company.
- CIN/LLPIN
U24232RJ2012PTC038361
- Company No.
038361
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
26 Mar 2012
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Jaipur
Industry
Company Details
- Location
Jaipur, Rajasthan, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Asia Biotech Private Limited offer?
Asia Biotech Private Limited offers a wide range of products and services, including Ayurvedic,Herbal Products & Medicine, Herbal Capsules, Ayurvedic Herbal Syrups & Tonics, Herbal Body Care Cosmetics, Kesh King Hair Oil, Diabetic Herbal Medicine, Diabetes Powder, Mineral Supplement, Calcium Syrup, Weight Loss Supplement.
Who are the key members and board of directors at Asia Biotech?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ashish Khandelwal  | Director | 21-Jul-2017 | Current |
| Nirmla Khandelwal | Director | 29-Aug-2020 | Current |
Financial Performance of Asia Biotech.
Asia Biotech Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 9.53% decrease. The company also saw a substantial fall in profitability, with a 20.81% decrease in profit. The company's net worth moved up by a moderate rise of 7.05%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Asia Biotech?
In 2023, Asia Biotech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 24 Mar 2021 | ₹1.30 M | Open |
Hdfc Bank Limited Creation Date: 27 Sep 2019 | ₹1.05 Cr | Open |
Bank Of Baroda Creation Date: 28 Jun 2012 | ₹5.50 M | Satisfied |
How Many Employees Work at Asia Biotech?
Unlock and access historical data on people associated with Asia Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Asia Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Asia Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
